Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2001-10-30
2003-03-04
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
06528540
ABSTRACT:
BACKGROUND OF THE INVENTION
Esmolol hydrochloride is a short-acting beta-blocker used for treatment or prophylaxis of cardiac disorders in mammals. Most of the currently available beta-blockers are stable drugs which can be administered to cardiac patients over relatively long periods of time. However, it is often desirable in the critical care setting to quickly reduce heart work or improve rhythmicity during a cardiac crisis, e.g., during or shortly after a myocardial infarction. Conventional beta-blocking agents can be employed for such treatment, but their long durations of action can cause undesirable side effects.
Esmolol hydrochloride contains an ester functional group and possesses the typical beta-adrenergic blocking activity. However, it differs from conventional beta-blocking compound in that esmolol hydrochloride has a short duration in vivo due to the presence of the ester group. Thus, esmolol hydrochloride is advantageous compared to the conventional beta-blockers because of its unique short-acting activity. However, the ester group in esmolol hydrochloride is found to be unstable in an aqueous environment because of it extreme susceptibility to hydrolytic degradation.
The stability of esmolol in water is mediated by the rate of acid/base hydrolysis of the labile aliphatic methyl ester group. In the past, the rate of degradation of esmolol hydrochloride has been reduced by the use of acetate as a buffer, maintaining the pH as close to 5.0 as possible, minimizing the concentration of esmolol in the solution, and minimizing the concentration of buffer used. Prior art formulations maintain a reasonably long shelf-life, however, they suffer from severe degradation upon autoclaving. As a result, prior art formulations are prepared aseptically. C.f. U.S. Pat. Nos. 4,857,552 and 5,107,609. U.S. Pat. No. 4,857,552 discloses a ready-to-use formulation suitable for vial packaging containing esmolol in an aqueous buffer solution. U.S. Pat. No. 5,107,609 discloses a concentrated formulation suitable for ampul packaging containing esmolol in an aqueous buffer solution, with propylene glycol and ethanol added to increase solubility of the esmolol. Prior to administration, this ampul formulation is diluted to appropriate dosage level with a compatible isotonic solution such as one containing dextrose, lactated Ringer's solution, sodium chloride or potassium chloride.
However, microbiological contamination of the product during dilution/aseptic handling is possible in both vial and ampul presentations. Therefore, terminal sterilization is typically preferred by regulatory authorities as a way of reducing microbiological burden and to ensure the safety of the finished product.
BRIEF SUMMARY OF THE INVENTION
The present invention relates to an aqueous, sterile pharmaceutical composition suitable for parenteral administration for the treatment of cardiac conditions comprising methyl-3-[4-(2-hydroxy-3-isopropylamino)propoxy]phenylpropionate hydrochloride (esmolol hydrochloride), a buffering agent and an osmotic-adjusting agent, and further relates to a method for its manufacture in a container.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a stable, parenteral composition containing esmolol hydrochloride and a pharmaceutically acceptable buffering agent and an osmotic adjusting agent to adjust the tonicity of the solution. The composition is packaged in a sealed container and subjected to terminal sterilization via autoclaving to reduce the microbiological burden of the formulation. Esmolol hydrochloride formulations of the prior art cannot survive autoclaving. The present invention is stable against hydrolytic degradation and other adverse chemical reactions, and possesses a pharmaceutically-acceptable shelf-life.
“Stable”, as used in the context of this application, means remaining in a state or condition that is suitable for administration to a patient. Formulations according to the present invention are found to be stable when maintained at room temperature for at least 12 months, and are generally stable at room temperature for 12 to 24 months.
A “sterile” composition, as used in the context of this application, means a composition that has been brought to a state of sterility and has not been subsequently exposed to microbiological contamination, i.e. the container holding the sterile composition has not been compromised. Sterile compositions are generally prepared by pharmaceutical manufacturers in accordance with current Good Manufacturing Practice (“cGMP”) regulations of the U.S. Food and Drug Administration.
The product can take the form of a sterile, ready-to-use formulation for infusion. This avoids the inconvenience of diluting a concentrated esmolol small volume parenteral formulation into infusion diluents prior to infusion, as well as eliminates the risk of microbiological contamination during aseptic handling and any potential calculation or dilution error. Such formulations, not being prepared from a concentrate, will be essentially free from propylene glycol and ethanol. The product can also take the form of a concentrated formulation which must be diluted prior to administration.
The aqueous, sterile pharmaceutical composition of the present invention is suitable for parenteral administration to a patient. For example, the composition may be administered in the form of a bolus injection or intravenous infusion. Suitable routes for parenteral administration include intravenous, subcutaneous, intradermal, intramuscular, intraarticular, and intrathecal. The ready-to-use formulation of the invention is preferably administered by intravenous infusion.
Containers suitable according to the present invention are those known in the art. They include vial, syringe, bag, bottle and ampul presentations. Containers may be fabricated from glass or from polymeric materials. Ready-to-use formulations are typically packaged in vials, syringes, bags and bottles, while concentrated formulations are typically packaged in ampuls.
The pH of the composition greatly effects its stability. The pH should be between 3.5 and 6.5, preferably between 4.5 and 5.5, more preferably about 5.0. The pH can be adjusted as known in the art by addition of sodium hydroxide or hydrochloric acid.
Esmolol hydrochloride is present in the instant composition in an amount ranging from 0.1-500 mg/ml. Ready-to-use formulations may contain 0.1-100 mg/ml, preferably 1-20 mg/ml, more preferably 1-10 mg/ml. Concentrated formulations may contain 100-500 mg/ml, preferably 100-250 mg/ml.
Suitable buffering agents are known in the art, and are present in the composition in a concentration ranging from 0.01-2 M. Ready-to-use formulations typically have buffering agent concentrations of 0.01-0.5 M, preferably 0.02-0.1 M. Concentrated formulations typically have buffering agent concentrations of 0.5-2 M. Buffering agents include acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine. The preferred buffering agent comprises a combination of sodium acetate and glacial acetic acid.
Suitable osmotic-adjusting agents are known in the art, and are present in the composition in an amount ranging from 1-500 mg/ml. Osmotic-adjusting agents include sodium chloride, dextrose, sodium bicarbonate, calcium chloride, potassium chloride, sodium lactate, Ringer's solution and lactated Ringer's solution. Preferred are sodium chloride and dextrose. Ready-to-use formulations may contain 1-100 mg/ml osmotic-adjusting agent; preferably 4-60 mg/ml sodium chloride, more preferably 4-10 mg/ml sodium chloride; or dextrose, with or without sodium chloride, in an amount ranging from 25-60 mg/ml. Dextrose is preferably present in the composition of the present invention at a level no greater than 5% (weight by weight) in combination with sodium chloride. Concentrated formulations may contain 50-500 mg/ml osmotic-adjusting agent.
Compositions according to the present invention can be prepared into small volume parenteral (SVP) and large volume parenteral (LVP) dosage
Liu Jie
Owoo George
Pejaver Satish K.
Baxter International Inc.
Henley III Raymond
Jaconetty Kenneth E.
LandOfFree
Esmolol formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Esmolol formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Esmolol formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3003166